

→

PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	09/724,319
Sheet	1	of	4
		Examiner Name	Nichols, C. J.
		Art Unit	1647
		Attorney Docket Number	15270J-004743US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Column, Lines, Where Relevant Passages or Relevant Figures Appear
✓	578	6,875,434	04-05-2005	Schenk	
	577	6,866,849	03-16-2005	Schenk	
	575	6,868,850	03-15-2005	Schenk	
	578	6,818,218	11-16-2004	Schenk	
	563	6,767,637	09-07-2004	Schenk et al.	
	572	6,761,888	07-13-2004	Schenk	
	562	6,750,324	08-15-2004	Schenk et al.	
	573	6,743,427	06-01-2004	Schenk	
	544	2003/0147882 A1	08-07-2003	Solomon et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	
	518	6,281,569	07-17-2001	Comis et al.	
	510	6,022,859	02-08-2000	Kiessling, et al.	
	512	5,891,991	04-08-1999	Wasco et al.	
	515	5,652,334	07-29-1997	Roberts	
	574	5,576,184	11-19-1996	Better et al.	
	513	5,514,548	05-07-1996	Krebbet et al.	
	514	5,470,961	11-28-1995	Roberts	
	543	5,278,049	01-11-1994	Baker et al.	
	548	5,096,706	03-17-1992	Flint	
↓	570	4,912,208	03-27-1990	Goldgaber et al.	

Examiner Signature	<i>Jahnalyx Ryles</i>	Date Considered	7-22-05
--------------------	-----------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60479618 v1

BEST AVAILABLE COPY

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Nichols, C. J.
Attorney Docket Number	16270J-004743US

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>4</sup> (if known)				
OF	533	AU	199870091		07-01-1999			
	523	EP	752 888	B1	01-28-1998			
	579	WO	04/031400	A2	04-15-2004			
	571	WO	04/13172	A2 A3	02-12-2004			
	557	WO	02/68307	A2	11-07-2002			
	556	WO	02/88306	A2	11-07-2002			
	529	WO	00/68263	A2	11-16-2000			
	519	WO	00/26238	A2	05-11-2000			
	555	WO	00/23082	A1	04-27-2000			
	522	WO	00/20027	A2	04-13-2000			
	528	WO	99/06587	A2	02-11-1999			
	520	WO	98/22120	A1	05-26-1998			
	530	WO	98/08868	A1	03-05-1998			
	521	WO	98/05350	A1	02-12-1998			
	525	WO	98/02462	A1	01-22-1998			
	527	WO	97/32017	A1	09-04-1997			
	528	WO	97/08320	A1	03-06-1997			
	532	WO	96/37621	A2	11-28-1996			
	518	WO	95/23186	A1	08-31-1995			
	531	WO	95/08999	A1	04-06-1995			
	524	WO	95/05393	A2	02-23-1995			
	517	WO	94/05311	A1	03-17-1994			

Examiner Signature

*Debra Lynn Lyle*

Date Considered

7-22-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60479618 v1

BEST AVAILABLE COPY

→

PTO/SB/09B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	09/724,319
(use as many sheets as necessary)			Filing Date	November 27, 2000
			First Named Inventor	Schenk, D. B.
			Art Unit	1647
			Examiner Name	Nichols, C. J.
Sheet	3	of	4	Attorney Docket Number
15270J-004743US				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
JF	580	BARD et al., "Epitope and Isotype specificities of antibodies to $\beta$ -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <i>PNAS</i> , 100(4):2023-2028 (2003).
	581	BELLOTTI et al., "Application of Monoclonal Anti-Idiotypes in the Study of AL Amyloidoses: Therapeutic Implications," <i>Renal Failure</i> , 15(3):365-371 (1993).
	588	BENJAMINI et al., from <i>IMMUNOLOGY A Short Course</i> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.
	540	BEMKIRANE, et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>J. Biol. Chem.</i> , 268(23):26279-26285 (1993).
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <i>J. Biol. Chem.</i> , 276(24):21562-70 (2001).
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <i>J. Mol. Biol.</i> , 186:651-663 (1985).
	509	CIRRITO et al., "Amyloid $\beta$ and Alzheimer disease therapeutics: the devil may be in the details," <i>J. Clin. Invest.</i> , 112:321-323 (2000).
	541	CRIBBS et al., "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <i>J. Biol. Chem.</i> , 272:7431-7436 (1997).
	539	FINDEIB et al., "Modified peptide inhibitors of amyloid $\beta$ -peptide polymerization," <i>Biochemistry</i> , 38:6791-6800 (1999).
	538	FLOOD, et al., "Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid $\beta$ protein," <i>PNAS</i> , 91:380-384 (1994).
	585	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology, fourth edition</i> , W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).
	569	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <i>Eur. J. Immunol.</i> , 9:657-659 (1979).
	534	HOCK et al., "Antibodies against $\beta$ -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <i>Neuron</i> , 38:542-554 (2003).
↓	548	IRIZARRY et al., "A $\beta$ Deposition Is Associated with Neuril Changes, but not with Overt Neuronal Loss In the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <i>J. Neuroscience</i> , 17(18):7053-7059 (1997).

Examiner Signature	<i>Johnalyon Leyles</i>	Date Considered	7-22-05
--------------------	-------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60479518 vi

BEST AVAILABLE COPY

→

PTO/SBU-083 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

BEST AVAILABLE COPY

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1647
				Examiner Name	Nichols, C. J.
Sheet	4	of	4	Attorney Docket Number	15270J-004743US

	560	JAHRLING et al., "Opsonization of Alphaviruses in Hamsters." <i>J. Medical Virology</i> , 12:1-16 (1983).
	547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) In Amyloid Formation <i>In Vitro</i> ." <i>J. Mol. Biol.</i> , 287:781-798 (1999).
	554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation." <i>Protein Engineering</i> , 4(7):773-783 (1991).
	553	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R182G) as mucosal adjuvants." <i>Neurobiology of Aging</i> , 23(8):891-1000 (2002).
	531	LEVERONE et al., "Aβ1-15 is less immunogenic than Aβ1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting." <i>Vaccine</i> , 21:2197-2206 (2003).
	545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing VT17F β-Amyloid Precursor Protein and Alzheimer's Disease." <i>J. Neuroscience</i> , 16(18):5795-5811 (1996).
	568	NOVOTNY et al., "Structural Invariants of antigen binding: Comparison of Immunoglobulin V <sub>L</sub> -V <sub>H</sub> and V <sub>L</sub> -V <sub>L</sub> domain dimers." <i>PNAS</i> , 82:4592-4596 (1985).
	564	PCT Search Report of 12/14/04 for application PCT/US04/02856
	838	SELA et al., "Different roles of D-amino acids in immune phenomena." <i>FASEB J.</i> , 11(5):449-456 (1999)..
	552	SIGURDSSON et al., "Immunization with a Nonfibrillar/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice." <i>Am. J. Pathology</i> , 159(2):439-447 (2001).
	549	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease." <i>Expert Opin. Biol. Ther.</i> , 2(8):907-917 (2002).
	537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands." <i>J. Biol Chem.</i> , 272(18):12601-12605 (1997).
	535	VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents." <i>Curr. Opin. Biotechnol.</i> , 9(4):377-382 (1998).
	569	VERSHIGORA A. E. OBSHCHAYA IMMUNOLOGIYA, pages 35, 229-231 and 152-153.
	567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity." <i>J. Exp. Med.</i> , 132:211-250 (1970).

Examiner Signature	<i>Johnalyse Lyles</i>	Date Considered	7-22-05
--------------------	------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60479618 v1